Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2853. doi: 10.1073/pnas.1505059112. Epub 2015 May 4. No abstract available.

2.

Novel recurrently mutated genes in African American colon cancers.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1149-54. doi: 10.1073/pnas.1417064112. Epub 2015 Jan 12.

3.

Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation.

Reynolds RC, Campbell SR, Fairchild RG, Kisliuk RL, Micca PL, Queener SF, Riordan JM, Sedwick WD, Waud WR, Leung AK, Dixon RW, Suling WJ, Borhani DW.

J Med Chem. 2007 Jul 12;50(14):3283-9. Epub 2007 Jun 15.

PMID:
17569517
4.

On systems and control approaches to therapeutic gain.

Radivoyevitch T, Loparo KA, Jackson RC, Sedwick WD.

BMC Cancer. 2006 Apr 25;6:104.

5.

A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage.

Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA.

Oncogene. 2003 Oct 20;22(47):7376-88. Review.

PMID:
14576845
6.

Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.

Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ.

Cancer Res. 2001 Nov 15;61(22):8290-7.

7.

Mismatch repair and drug responses in cancer.

Sedwick WD, Markowitz SD, Veigl ML.

Drug Resist Updat. 1999 Oct;2(5):295-306.

PMID:
11504504
8.

Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability.

Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz SD, Sedwick WD.

Oncogene. 2000 Apr 27;19(18):2249-56.

9.

Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells.

Chen WD, Eshleman JR, Aminoshariae MR, Ma AH, Veloso N, Markowitz SD, Sedwick WD, Veigl ML.

J Natl Cancer Inst. 2000 Mar 15;92(6):480-5.

PMID:
10716966
10.

Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.

Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, Willson JK, Schwartz S, Markowitz SD.

Oncogene. 1998 Aug 13;17(6):719-25.

11.

Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702.

12.

Increased transversions in a novel mutator colon cancer cell line.

Eshleman JR, Donover PS, Littman SJ, Swinler SE, Li GM, Lutterbaugh JD, Willson JK, Modrich P, Sedwick WD, Markowitz SD, Veigl ML.

Oncogene. 1998 Mar 5;16(9):1125-30.

13.

Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability.

Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD.

Oncogene. 1996 Apr 4;12(7):1425-32.

PMID:
8622858
14.

Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.

Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, Veigl ML, Sedwick WD, Markowitz SD.

Oncogene. 1995 Jan 5;10(1):33-7.

PMID:
7824277
15.
16.

Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.

Sedwick WD, Anderson RD, Baxter J, Donover S, Schneiter S, Veigl ML.

Mutat Res. 1995 Jan;326(1):17-27.

PMID:
7528882
17.

Molecular analysis of hypoxanthine phosphoribosyltransferase gene deletions induced by alpha- and X-radiation in human lymphoblastoid cells.

Bao CY, Ma AH, Evans HH, Horng MF, Mencl J, Hui TE, Sedwick WD.

Mutat Res. 1995 Jan;326(1):1-15.

PMID:
7528877
18.

Excision repair reduces doxorubicin-induced genotoxicity.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Mutat Res. 1993 Oct;294(3):215-22.

PMID:
7692261
19.

Sequencing of double-stranded polymerase chain reaction products for mutation analysis.

Anderson RD, Bao CY, Minnick DT, Baxter J, Veigl ML, Sedwick WD.

Mutat Res. 1993 Jul;288(1):181-5.

PMID:
7686261
20.
21.

Mutational specificity of 1,3-bis-(2-chloroethyl)-1-nitrosourea in a Chinese hamster ovary cell line.

Minnick DT, Veigl ML, Sedwick WD.

Cancer Res. 1992 Sep 1;52(17):4688-95.

22.

DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Cancer Res. 1991 Aug 1;51(15):3930-7.

23.

Specificities mediated by neighboring nucleotides appear to underlie mutation induced by antifolates in E. coli.

Veigl ML, Schneiter S, Mollis S, Sedwick WD.

Mutat Res. 1991 Jan;246(1):75-91.

PMID:
1986269
24.

Rapid mapping of deletion and duplication mutations by the polymerase chain reaction.

Anderson RD, Veigl ML, Sedwick WD.

Biochem Biophys Res Commun. 1990 Jul 31;170(2):416-20. No abstract available.

PMID:
2200400
25.

Phase I studies of recombinant interferon-gamma.

Laszlo J, Goldstein D, Gockerman J, Hood L, Huang AT, Triozzi P, Sedwick WD, Koren H, Ellinwood EH, Tso CY.

J Biol Response Mod. 1990 Apr;9(2):185-93.

PMID:
2160521
26.
27.

The uses and limitations of calmodulin antagonists.

Veigl ML, Klevit RE, Sedwick WD.

Pharmacol Ther. 1989;44(2):181-239. Review. No abstract available.

PMID:
2519344
28.

Base stacking and molecular polarizability: effect of a methyl group in the 5-position of pyrimidines.

Sowers LC, Shaw BR, Sedwick WD.

Biochem Biophys Res Commun. 1987 Oct 29;148(2):790-4.

PMID:
3689373
29.

DNA base modification: ionized base pairs and mutagenesis.

Sowers LC, Shaw BR, Veigl ML, Sedwick WD.

Mutat Res. 1987 Apr;177(2):201-18.

PMID:
3561423
30.

Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U).

Richards RG, Brown OE, Gillison ML, Sedwick WD.

Mol Pharmacol. 1986 Dec;30(6):651-8.

PMID:
3491287
31.

Induction of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells by gamma interferon.

Triozzi PL, Sedwick WD, Iland HJ, Richards RG, Laszlo J.

J Biol Response Mod. 1986 Dec;5(6):562-70.

PMID:
3098928
32.
33.

Induction of myeloid differentiation of HL-60 cells with naphthalene sulfonamide calmodulin antagonists.

Veigl ML, Sedwick WD, Niedel J, Branch ME.

Cancer Res. 1986 May;46(5):2300-5.

35.

Overcoming methotrexate resistance by a lipophilic antifolate (BW 301U): from theory to models to practice.

Laszlo J, Iland HJ, Sedwick WD.

Adv Enzyme Regul. 1985;24:357-75. Review.

PMID:
3915188
36.

Misincorporation of deoxyuridine in human cells: consequences of antifolate exposure.

Richards RG, Brown OE, Sedwick WD.

Basic Life Sci. 1985;31:149-62.

PMID:
3873237
37.

Differences in calmodulin levels of normal and transformed cells as determined by culture conditions.

Veigl ML, Vanaman TC, Branch ME, Sedwick WD.

Cancer Res. 1984 Aug;44(8):3184-9.

38.

Calcium and calmodulin in cell growth and transformation.

Veigl ML, Vanaman TC, Sedwick WD.

Biochim Biophys Acta. 1984;738(1-2):21-48. Review. No abstract available.

PMID:
6331500
39.

The occurrence and consequences of deoxyuridine in DNA.

Richards RG, Sowers LC, Laszlo J, Sedwick WD.

Adv Enzyme Regul. 1984;22:157-85.

PMID:
6147963
41.

Calmodulin and Ca2+ in normal and transformed cells.

Veigl ML, Sedwick WD, Vanaman TC.

Fed Proc. 1982 May;41(7):2283-8.

PMID:
6281082
42.

Toxicity of methotrexate and metoprine in a dihydrofolate reductase gene-amplified mouse cell line.

Hamrell M, Laszlo J, Brown OE, Sedwick WD.

Mol Pharmacol. 1981 Nov;20(3):637-43. No abstract available.

PMID:
7329406
43.

Transient induction of phenotypic resistance in human lymphoblastoid cells following sequential use of two antifolates.

Hamrell MR, Laszlo J, Sedwick WD.

Mol Pharmacol. 1981 May;19(3):491-5. No abstract available.

PMID:
7266473
44.

Human plasma and amino acids as moderators of uptake and metabolic consequences of antifolates in WIL-2 and human leukemia cells.

Fyfe MJ, Sedwick WD, Brown OE, Laszlo J.

J Natl Cancer Inst. 1981 Mar;66(3):445-51.

PMID:
6937701
46.

An antifolate-induced lesion in newly synthesized DNA.

Sedwick WD, Laszlo J.

Adv Enzyme Regul. 1980;19:295-308. No abstract available.

PMID:
7337030
47.

Deoxyuridine incorporation as a useful measure of methotrexate and metoprine uptake and metabolic effectiveness.

Sedwick WD, Fyfe MJ, Brown OE, Frazer TA, Kutler M, Laszlo J.

Mol Pharmacol. 1979 Sep;16(2):607-13. No abstract available.

PMID:
514260
48.
49.

Comparative studies of methotrexate and metoprine: metabolic toxicity and cell killing.

Sedwick WD, Fyfe MJ, Hamrell M, Laszlo J.

Adv Enzyme Regul. 1978;17:399-416. No abstract available.

PMID:
294129
50.

Supplemental Content

Loading ...
Support Center